AI주식인사이트AI Stock Insight
C

유틸렉스

263050KOSDAQ기초 의약물질 제조업

49.9 / 100

Reference Date: 2026-07-24

Financial Score14.0 / 40
News Sentiment16.9 / 25
Momentum12.0 / 20
Disclosure7.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Utillex is a biotech company established in 2015, focusing on R&D of immunotherapies such as CAR-T and antibody-based treatments. Its key pipeline, EU307, is a 4th-generation armored CAR-T therapy targeting GPC3 in solid tumors, while EU103 converts M2 macrophages to M1 to enhance immune responses, both currently in Phase I clinical trials. The company also operates IT services and research-related business.

Number of Employees

119people

Average Salary

55.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 25.444.0Point
PBR
2.24Industry Average 1.261.0Point

1.8x industry avg (risky)

ROE
-88.55Industry Average -6.033.5Point

14.7x industry avg (excellent)

Debt Ratio
21.94Industry Average 6.620.0Point

3.3x industry avg (risky)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲3572.1% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲19.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -60.4% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Detailed Momentum

52-week position3.0Point

52w lower range (24%)

Current 959Won52-week high 1,82852-week low 683
1-month return3.0Point

1m 0% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

8 totalPositive 0Neutral 7Negative 1
  • Neutral주주명부폐쇄기간또는기준일설정2026-07-16
  • Neutral주주총회소집결의 (임시주주총회)2026-07-16
  • Neutral기타시장안내 (정리매매 보류 관련)2026-07-03
  • Neutral주권매매거래정지 (투자자 보호)2026-07-03
  • Neutral기타경영사항(자율공시) (상장폐지결정 효력정지 등 가처분 신청)2026-07-03